Mark Fitzpatrick Net Worth

The estimated Net Worth of Mark J. Fitzpatrick is at least $1.42 Million dollars as of 4 December 2020. Mr. Fitzpatrick owns over 10,000 units of Chiasma Inc stock worth over $73,741 and over the last 9 years he sold CHMA stock worth over $0. In addition, he makes $1,346,300 as President and Chief Financial Officer at Chiasma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Fitzpatrick CHMA stock SEC Form 4 insiders trading

Mark has made over 2 trades of the Chiasma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CHMA stock worth $26,000 on 4 December 2020.

The largest trade he's ever made was exercising 10,000 units of Chiasma Inc stock on 4 December 2020 worth over $26,000. On average, Mark trades about 2,452 units every 89 days since 2016. As of 4 December 2020 he still owns at least 19,612 units of Chiasma Inc stock.

You can see the complete history of Mr. Fitzpatrick stock trades at the bottom of the page.

Mark Fitzpatrick biography

Mark J. Fitzpatrick is no longer serves as President, Chief Financial Officer of the Company effective 6/30/2021. He has been our President since October 2016 and previously served as our Chief Executive Officer and a member of our Board of Directors from October 2016 to June 2019 and Chief Financial Officer from June 2015 to October 2016. Prior to joining us, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. He also held the position of Chief Financial Officer at Proteon Therapeutics, Inc., RenaMed Biologics, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987.

What is the salary of Mark Fitzpatrick?

As the President and Chief Financial Officer of Chiasma Inc, the total compensation of Mark Fitzpatrick at Chiasma Inc is $1,346,300. There are 2 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.

How old is Mark Fitzpatrick?

Mark Fitzpatrick is 57, he's been the President and Chief Financial Officer of Chiasma Inc since 2019. There are 4 older and 8 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.

What's Mark Fitzpatrick's mailing address?

Mark's mailing address filed with the SEC is C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTON EXECUTIVE PARK, SUITE 202, NEWTON, MA, 02459.

Insiders trading at Chiasma Inc

Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke, and John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.

What does Chiasma Inc do?

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Complete history of Mr. Fitzpatrick stock trades at Chiasma Inc and Allena Pharmaceuticals Inc

Chiasma Inc executives and stock owners

Chiasma Inc executives and other stock owners filed with the SEC include:

• Raj Kannan,
  Chief Executive Officer, Director
• anand Varadan,
  Executive Vice President, Chief Commercial Officer
• Mark Fitzpatrick,
  President, Chief Financial Officer
• William Ludlam,
  Senior Vice President - Clinical Development and Medical Affairs
• Lee Giguere,
  Vice President, General Counsel, Secretary
• Drew Enamait,
  Vice President, Finance and Administration, Principal Accounting Officer
• Roni Mamluk,
  Director
• David Stack,
  Independent Chairman of the Board
• Scott Minick,
  Independent Director
• John Scarlett,
  Independent Director
• John Thero,
  Independent Director
• Todd Foley,
  Independent Director
• Bard Geesaman,
  Independent Director
• Ashley Robinson,
  IR Contact Officer
• Health Ventures Lp Wertheim...,
  
• Bio Ventures Iv Qp Lpevnin ...,
  
• Ansbert Gadicke,
  Director
• Mark Leuchtenberger,
  CEO, President
• James R Tobin,
  Director
• Tara Mc Carthy,
  General Counsel and Secretary
• Vincent J Miles,
  Director
• Llp Abingworth,
  10% owner
• John Brendan Doyle,
  Chief Financial Officer
• Capital, L.P. Stonepine,
  10% owner